Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1679
Peer-review started: December 18, 2014
First decision: March 6, 2015
Revised: April 8, 2015
Accepted: April 16, 2015
Article in press: April 20, 2015
Published online: June 28, 2015
Processing time: 194 Days and 5.6 Hours
The intestine of the human contains a dynamic population of microbes that have a symbiotic relationship with the host. In addition, there is an effect of the intestinal microbiota on metabolism and digestion. Non-alcoholic fatty liver disease (NAFLD) is a common cause worldwide of hepatic pathology and is thought to be the hepatic manifestation of the metabolic syndrome. In this review we examine the effect of the human microbiome on the components and pathogenesis of the metabolic syndrome. We are now on the threshold of therapeutic interventions on the human microbiome in order to effect human disease including NAFLD.
Core tip: The human intestine contains more bacterial cells than mammalian cells. These have a symbiotic relationship with the host. Non-alcoholic fatty liver disease is the hepatic manifestation of the metabolic syndrome and a major cause of hepatic morbidity as a consequence of the obesity epidemic. We examine the effect of the human microbiome on the components of the metabolic syndrome and fatty liver and mention the possibility of therapeutic interventions in humans.